Featuring Expert Speakers
Orphan Drugs & Rare Diseases Global Congress 2022 Europe
- Doug Danison, Head of Europe, bluebird bio
- Pedro Franco, Director for Global Regulatory & Scientific Policy (GRASP), Merck
- Helena Baker RGN, CEO, Rare Disease Nurse Network
- Emily Crossley, Co-founder, Duchenne UK
- Nick Sireau, PhD, Chair and CEO, AKU Society
- Owen Marks, Country Head for Rare Diseases Unit, Pfizer UK*
- Femida Gwadry-Sridhar, CEO and Founder, Pulse Infoframe Inc.
- Senior Representative, Rare Diseases Unit, Pfizer, UK
- Lesha D. Shah, MD, Medical Director, Icahn School of Medicine, Mount Sinai
- Philippa Norman, Projects Coordinator, Findacure
- Elisabetta Zanon, Director, EU Public Affairs & Advocacy, European Alliance for Regenerative Medicine
- Josie Godfrey, Director, JG Zebra Consulting
- Lindsay Weaver, Co-Founder & CEO, Realise Advocacy, Trustee, Medics 4 Rare Diseases
- Christian Girard, Strategic Consultant, Orphan Drugs Industry Advisory & Intelligence
- Senior representative, Illingworth Research Group, a Syneos Health Company
- Sophie Laribiere, Sr Director, Global Regulatory Affairs, Alexion Pharmaceuticals
- Rhian Kiely, RWE Commercial Director, Europe, Open Health Evidence & Access
- Martina Garau , Director, Office of Health Economics
- Andrew Kim, VP International Strategic Operations & General Manager, Global Distributor Markets, Blueprint Medicines
- Ryotaro Ishikawa, Global Market Access Director, Novartis
- Simu Thomas PhD, Vice President, Global Head HEOR, Alexion Pharmaceuticals
- Keith White, Head, Global Market Access, Amylyx Pharmaceuticals
- Arvin M. Gouw, Ph.D., VP of Research & Development, Rare Genomics Institute
- Angela Columbano, Head Business Development & Partnership, Genethon
- Paul Beresford, International Biotech Executive
- Saira A. Jan, VP & Chief Pharmacy Officer, Horizon Blue Cross Blue Shield of New Jersey
- Paolo Morgese, EU Director Market Access, Alliance for Regenerative Medicine
- Manolo Bellotto, PhD, President, Gain Therapeutics SA
- Alexander Natz, LL.M., Secretary-General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- Karen Matthews, Business Development Manager, National Institute for Health Research*
- Kerry Leeson-Beevers, National Development Manager & Project Lead, Alström Syndrome*
- Senior Representative, National Institue for Health and Care Excellence (NICE)*
- Paul Greenland, President EMEA, Amryt Pharma
- Simon Jones, MD, Medical Director, NIHR Clinical Research Facility, NIHR
- Sheela Upadhyaya, Associate Director - Highly Specialised Technologies, NICE
- Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
- David Rose, BD, RARE Revolution Magazine, Ultra-Rare Disease Patient Speaker
- Karen Matthews, Business Development Manager, CRNCC, NIHR Clinical Research Network
- Eric Alton, Professor, Imperial College London, Head, UK CF Gene Therapy Consortium
- Joe Brice, Head, Franchise Public Affairs, EUCAN, Takeda*
- Farhat Khanim MD, Director of Research, Institute of Clinical Sciences, University of Birmingham
- Zizi Imatorbhebhe, MBA MS PMP® Senior Vice President, Global Strategy & Development, Rare Disease, Ergomed
- Daniel Lewi, Head of Business Development and Patient Advocacy, Pulse Infoframe Inc.
- David Ross, Patient Advocate, Rare Disease Mental Health
- Peter MacLennan, CEO, Tailored Clinical Research Solutions Ltd
- Juliet Hulse, Sr. Director, Global Research Nurse Strategy, Illingworth Research Group
- Carole Scrafton, CEO & Co-Founder, FibroFlutters
- And many more...

Ramona Reichenbach
Head Managed Access Center of Excellence (MACoE), Novartis